These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11499967)

  • 21. Blood supply safety: an NHLBI perspective.
    Glynn SA
    Transfusion; 2008 Aug; 48(8):1541-4. PubMed ID: 18713102
    [No Abstract]   [Full Text] [Related]  

  • 22. ['Variant of Creutzfeldt-Jacob disease and blood transfusion'; report of the Dutch Health Council].
    van Aken WG
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1444-7. PubMed ID: 11503311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Creutzfeldt-Jakob disease and blood products: FDA policy.
    Fratantoni JC
    Biologicals; 1998 Jun; 26(2):133-4. PubMed ID: 9811520
    [No Abstract]   [Full Text] [Related]  

  • 24. What future means to management of blood centres.
    van Aken WG
    Vox Sang; 1998; 74 Suppl 2():115-8. PubMed ID: 9704432
    [No Abstract]   [Full Text] [Related]  

  • 25. Geographic exposure risk of variant Creutzfeldt-Jakob disease in US blood donors: a risk-ranking model to evaluate alternative donor-deferral policies.
    Yang H; Huang Y; Gregori L; Asher DM; Bui T; Forshee RA; Anderson SA
    Transfusion; 2017 Apr; 57(4):924-932. PubMed ID: 28261810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study.
    Hewitt PE; Llewelyn CA; Mackenzie J; Will RG
    Vox Sang; 2006 Oct; 91(3):221-30. PubMed ID: 16958834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variant Creutzfeldt-Jacob disease - the availability of a screening test will be the beginning, not the end, of difficult transfusion-related issues.
    Sandler SG
    Curr Opin Hematol; 2006 Nov; 13(6):445-6. PubMed ID: 17053456
    [No Abstract]   [Full Text] [Related]  

  • 28. NBS approaches to the approval of suppliers of leucodepletion systems.
    Smith KJ
    Transfus Sci; 1998 Dec; 19(4):371-2. PubMed ID: 10351159
    [No Abstract]   [Full Text] [Related]  

  • 29. Operational and research approaches to universal leucodepletion in Scotland.
    Prowse C
    Transfus Sci; 1998 Dec; 19(4):367-9. PubMed ID: 10351158
    [No Abstract]   [Full Text] [Related]  

  • 30. [Blood transfusion and supply chain management safety].
    Quaranta JF; Caldani C; Cabaud JJ; Chavarin P; Rochette-Eribon S
    Presse Med; 2015 Feb; 44(2):214-20. PubMed ID: 25578550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UK patient first to contract vCJD via blood transfusion.
    Sibbald B
    CMAJ; 2004 Mar; 170(7):1087. PubMed ID: 15051685
    [No Abstract]   [Full Text] [Related]  

  • 32. New variant Creutzfeldt-Jakob disease and the blood supply: is it time to face the music?
    Hoey J; Giulivi A; Todkill AM
    CMAJ; 1998 Sep; 159(6):669-70. PubMed ID: 9780967
    [No Abstract]   [Full Text] [Related]  

  • 33. Insights into the management of emerging infections: regulating variant Creutzfeldt-Jakob disease transfusion risk in the UK and the US.
    Ponte ML
    PLoS Med; 2006 Oct; 3(10):e342. PubMed ID: 17076547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood supplies hit by vCJD fear.
    Strachan-Bennett S
    Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624
    [No Abstract]   [Full Text] [Related]  

  • 35. [Transfusion safety: emergent or hypothetical risks].
    Hervé P
    Transfus Clin Biol; 2000 Feb; 7(1):30-8. PubMed ID: 10730344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. UK approach to assessing assays and filters designed to reduce the risk of transfusion-transmitted vCJD.
    Thomas S; Turner ML; Williamson LM
    Transfus Clin Biol; 2013 Sep; 20(4):405-11. PubMed ID: 23928183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Creutzfeldt-Jakob disease and blood transfusion.
    Esmonde TF; Will RG; Slattery JM; Knight R; Harries-Jones R; de Silva R; Matthews WB
    Lancet; 1993 Jan; 341(8839):205-7. PubMed ID: 8093499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical approaches to limited resources.
    Lin CK
    Vox Sang; 2004 Jul; 87 Suppl 2():172-5. PubMed ID: 15209910
    [No Abstract]   [Full Text] [Related]  

  • 39. [Self-sufficiency, needs, prescription and safety of blood products].
    Folléa G; Monsellier M; Grimfeld A; Pelletier B; Lassale B; Morel P; Samama CM; Hermine O; Lefrère JJ
    Transfus Clin Biol; 2013 May; 20(2):139-43. PubMed ID: 23622841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease.
    Cooper JK; Andrews N; Ladhani K; Bujaki E; Minor PD
    Vox Sang; 2013 Oct; 105(3):196-204. PubMed ID: 23772892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.